Today’s antidepressants leave a third of patients behind. This mental health epidemic needs solutions, not wishful thinking.
CEO, Small Pharma
We’re on a mission to fast track the development of new therapies for patients affected by depression.
People deserve mental health therapies that are safe, work quickly and have long lasting effects, tackling the root causes rather than numbing the symptoms.
Who we are,
what we do
Find out more about our story and meet the team behind Small Pharma
‘We do have to start looking for a completely different approach, and try something completely out of the box.’
Dr Carol Routledge, CMSO
It has been a real pleasure working with Small Pharma since the launch of Drug Science’s Medical Psychedelics Working Group in July 2020. Small Pharma have been a partner since the beginning, together we have achieved much and have far-reaching plans for the future.
Prof Jo Neill
Traditional talk therapy can be extremely expensive and for some it takes years to process their psychological issues. Often it is those rare experiential moments when a re-enactment of old wounds surfaces that provide a real shift in the therapeutic process. Psychedelics reliably provide those experiential moments and thus hold great potential in catalysing therapy.
Michelle Baker Jones
Small Pharma’s endeavour to test DMT-assisted therapy for depression is not only interesting and timely but also very important. Their ambitious research program testing a short half-life powerful compound like DMT has the potential to make a massive positive difference for patients suffering depression.
Dr David Erritzoe
We’re committed to the safe trial of new medicines through a visionary drug development approach.
By driving innovation on known compounds, we aim to accelerate the development of new potential optimised medicines for treating challenging conditions underserved by existing treatments.
DMT based treatments may have incredible potential as fast acting antidepressant therapies.
They also have multiple benefits over existing treatments. Our core drug pipeline harnesses the potential of the short acting psychedelic, DMT, a naturally occurring compound found in plants and animals, which is believed to have possible medicinal properties.
Research & trials
See how Small Pharma is unlocking the potential of DMT based medicines through groundbreaking and accelerated R&D
Years of R&D development
Medicines in development
Active Phase I/IIa clinical trial